The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2025

Conditions

Chemotherapy-induced Thrombocytopenia

Interventions

DRUG

Hetrombopag

All the recruited 48 patients will take hetrombopag 5mg/day within 24 hours after chemotherapy

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER